BR112012026938A2 - Composição à base de fexofenadina e seu processo de preparação. - Google Patents

Composição à base de fexofenadina e seu processo de preparação.

Info

Publication number
BR112012026938A2
BR112012026938A2 BR112012026938A BR112012026938A BR112012026938A2 BR 112012026938 A2 BR112012026938 A2 BR 112012026938A2 BR 112012026938 A BR112012026938 A BR 112012026938A BR 112012026938 A BR112012026938 A BR 112012026938A BR 112012026938 A2 BR112012026938 A2 BR 112012026938A2
Authority
BR
Brazil
Prior art keywords
fexofenadine
preparation process
based composition
hot melt
melt coating
Prior art date
Application number
BR112012026938A
Other languages
English (en)
Inventor
Lesot Axelle
Lamoureux Gael
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42797556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012026938(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112012026938A2 publication Critical patent/BR112012026938A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Paints Or Removers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIÇÃO À BASE DE FEXOFENADINA E SEU PROCESSO DE PREPARAÇÃO. A presente invenção refere-se a grândulos de fexofenadina, a uma composição contendo-os e a um processo para o revestimento por fusão a quente de fexofenadina. O processo para o revestimento por fusão a quente de fexofenadina permite um mascaramento eficiente de seu sabor amargo sem, entretanto, retardar inaceitavelmente sua dissolução.
BR112012026938A 2010-04-21 2011-04-20 Composição à base de fexofenadina e seu processo de preparação. BR112012026938A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1053034A FR2959130A1 (fr) 2010-04-21 2010-04-21 Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
PCT/IB2011/002000 WO2011151733A2 (en) 2010-04-21 2011-04-20 Fexofenadine-based composition and preparation process therefor

Publications (1)

Publication Number Publication Date
BR112012026938A2 true BR112012026938A2 (pt) 2017-10-03

Family

ID=42797556

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012026596A BR112012026596A2 (pt) 2010-04-21 2011-04-20 método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas
BR112012026938A BR112012026938A2 (pt) 2010-04-21 2011-04-20 Composição à base de fexofenadina e seu processo de preparação.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112012026596A BR112012026596A2 (pt) 2010-04-21 2011-04-20 método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas

Country Status (22)

Country Link
US (2) US20130251794A1 (pt)
EP (2) EP2560612B1 (pt)
JP (2) JP2013525340A (pt)
KR (2) KR20130094716A (pt)
CN (2) CN103002874B (pt)
AR (2) AR081539A1 (pt)
AU (2) AU2011244020A1 (pt)
BR (2) BR112012026596A2 (pt)
CA (2) CA2796816A1 (pt)
CL (2) CL2012002898A1 (pt)
CO (2) CO6620042A2 (pt)
EA (2) EA201291089A1 (pt)
ES (2) ES2527390T3 (pt)
FR (1) FR2959130A1 (pt)
IL (2) IL222578A0 (pt)
MA (2) MA34226B1 (pt)
MX (1) MX2012012275A (pt)
PL (2) PL2560612T3 (pt)
SG (3) SG184950A1 (pt)
TW (2) TWI478713B (pt)
UY (2) UY33350A (pt)
WO (2) WO2011132167A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102349889B (zh) * 2011-11-01 2013-08-28 江苏先声药物研究有限公司 一种含有决奈达隆的组合物
JP5841433B2 (ja) * 2012-01-11 2016-01-13 日東電工株式会社 口腔内フィルム状基剤及び製剤
JP6245677B2 (ja) * 2012-01-20 2017-12-13 ニプロ株式会社 口腔内崩壊錠
JP6255908B2 (ja) * 2012-11-09 2018-01-10 大正製薬株式会社 固形製剤
FR2999937B1 (fr) * 2012-12-21 2015-01-09 Sanofi Sa Unite solide a haute teneur en fexofenadine et son procede de preparation
CN104274408A (zh) * 2013-07-10 2015-01-14 北京科信必成医药科技发展有限公司 一种熔融包衣的速释药物微粒及其制备方法
CN103610645B (zh) * 2013-11-25 2016-05-11 浙江万晟药业有限公司 一种非索非那定盐酸盐的药物组合物及制备方法
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2016120299A1 (en) * 2015-01-28 2016-08-04 Sanovel Ilac Sanayi Ve Ticaret A.S. Orally disintegrating formulations of dronedarone
US20180344648A1 (en) * 2015-11-30 2018-12-06 Piramal Enterprises Limited Clobazam tablet formulation and process for its preparation
EP3363429A1 (en) * 2017-02-20 2018-08-22 DSM IP Assets B.V. Process for the production of coated particles
EP3670489A1 (en) * 2018-12-21 2020-06-24 Dompé farmaceutici S.p.A. Co-crystal of ketoprofen, compositions comprising the same, process of producing the same, and uses thereof
JP2023549381A (ja) 2020-11-18 2023-11-24 バイオファーマ・シナジーズ，エス．エル． 抗ヒスタミン活性化合物を含む口内分散性粉末組成物
WO2022175829A1 (en) * 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions
WO2023126637A1 (en) * 2021-12-29 2023-07-06 Opella Healthcare Group Sas Compositions containing fexofenadine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
JPH07100665B2 (ja) * 1987-12-23 1995-11-01 信越化学工業株式会社 被覆薬剤の製造方法
US5296236A (en) * 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
DE69129036T2 (de) 1990-11-30 1998-07-30 Yamanouchi Pharma Co Ltd Überdeckte zusammensetzung mit schneller freisetzung
US5578322A (en) * 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
DE69313865T2 (de) * 1992-10-16 1998-02-12 Glaxo Group Ltd Geschmacksmaskierende zusammensetzungen von ranitidin
KR100405116B1 (ko) 1995-02-28 2004-02-05 아벤티스 파마슈티칼스 인크. 피페리디노알칸올화합물에대한약제학적조성물
US5846632A (en) * 1995-06-29 1998-12-08 Eastman Kodak Company Transfer support and method for fusing a transferrable image to a digital disc
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
FR2753904B1 (fr) * 1996-10-01 1998-10-30 Gattefosse Ets Sa Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication
US5891476A (en) * 1997-12-22 1999-04-06 Reo; Joe P. Tastemasked pharmaceutical system
US6274162B1 (en) * 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
FR2811912B1 (fr) * 2000-07-21 2003-02-07 Gattefosse Ets Sa Procede d'enrobage de particules solides par un agent thermofusible, et particules solides ainsi enrobees
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
FR2838647B1 (fr) * 2002-04-23 2006-02-17 Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant
CN1674874A (zh) * 2002-08-14 2005-09-28 纳幕尔杜邦公司 涂覆药物颗粒的方法
FR2848855B1 (fr) 2002-12-23 2005-02-11 Aventis Pharma Sa Compositions pour administration orale de principes actifs necessitant un masquage du gout
DE60308828T2 (de) * 2003-05-20 2007-05-24 Ethypharm Orale pharmazeutische Zusammensetzung mit verzögerter Freisetzung
FR2857263B1 (fr) * 2003-07-09 2005-09-09 Sanofi Synthelabo Nouvelle composition pharmaceutique solide comprenant de l'amisulpride
WO2005065639A2 (en) * 2003-11-21 2005-07-21 Torrent Pharmaceuticals Limited Novel pharmaceutical compositions
WO2005062722A2 (en) * 2003-11-21 2005-07-14 Sun Pharmaceutical Industries Limited Fexofenadine containing pharmaceutical formulation
TR200606412T2 (tr) 2004-03-19 2007-01-22 Eczaciba�I �Zg�N K�Myasal �R�Nler San. Ve T�C. A �. Lipit kaplı sefuroksim aksetil hazırlanması
US20070048373A1 (en) * 2005-08-30 2007-03-01 Cima Labs Inc. Dried milled granulate and methods

Also Published As

Publication number Publication date
CN103002874A (zh) 2013-03-27
FR2959130A1 (fr) 2011-10-28
TW201204415A (en) 2012-02-01
MA34226B1 (fr) 2013-05-02
SG10201506708UA (en) 2015-09-29
AR081539A1 (es) 2012-10-03
EP2560613A2 (en) 2013-02-27
CO6620043A2 (es) 2013-02-15
MX2012012275A (es) 2012-11-16
AU2011244020A1 (en) 2012-11-08
WO2011132167A1 (en) 2011-10-27
JP2013525340A (ja) 2013-06-20
EP2560612A1 (en) 2013-02-27
CN103002874B (zh) 2015-04-08
WO2011151733A3 (en) 2012-01-26
SG184951A1 (en) 2012-11-29
ES2525163T3 (es) 2014-12-18
EP2560612B1 (en) 2014-09-03
IL222578A0 (en) 2012-12-31
CA2796816A1 (en) 2011-12-08
UY33351A (es) 2011-12-01
AR080934A1 (es) 2012-05-16
KR20130094716A (ko) 2013-08-26
PL2560613T3 (pl) 2015-03-31
PL2560612T3 (pl) 2015-03-31
TW201206434A (en) 2012-02-16
EA201291089A1 (ru) 2013-05-30
KR20130080428A (ko) 2013-07-12
AU2011262319A1 (en) 2012-11-08
CA2796821A1 (en) 2011-10-27
CN102946857A (zh) 2013-02-27
EP2560613B1 (en) 2014-10-15
IL222576A0 (en) 2012-12-31
TWI478713B (zh) 2015-04-01
BR112012026596A2 (pt) 2016-07-12
ES2527390T3 (es) 2015-01-23
JP2013525341A (ja) 2013-06-20
US20130183382A1 (en) 2013-07-18
SG184950A1 (en) 2012-11-29
EA201291088A1 (ru) 2013-03-29
US20130251794A1 (en) 2013-09-26
WO2011151733A2 (en) 2011-12-08
MA34227B1 (fr) 2013-05-02
CL2012002898A1 (es) 2013-03-01
CO6620042A2 (es) 2013-02-15
UY33350A (es) 2011-12-01
CL2012002909A1 (es) 2013-01-25

Similar Documents

Publication Publication Date Title
BR112012026938A2 (pt) Composição à base de fexofenadina e seu processo de preparação.
BR112014017021A8 (pt) inibidores de irak e usos dos mesmos
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
CO6551721A2 (es) Moduladores de cinasa novedosos
BR112013019223A2 (pt) forma de dosagem para liberação modificada, processo para a fabricação de um comprimido e processo para a fabricação de uma forma de dosagem oral
BR112015001101A2 (pt) formas cristalinas de um inibidor de prolil hidroxilase
MX2020003112A (es) Composiciones de biguanida y metodos para tratar trastornos metabolicos.
BR112012032816A2 (pt) composição farmacêutica de liberação controlada, e, métodos para reduzir o efeito alimentar de uma composição de liberação controlada, reduzir o período de tempo necessário para que seja alcançado um estado estável para a metformina, para aperfeiçoar a biodisponibilidade de uma forma de dosagem de liberação controlada de matriz
DK2673262T3 (da) Fremgangsmåder til fremstilling af quinolinforbindelser og farmaceutiske sammensætninger indeholdende sådanne forbindelser
BR112014030655A8 (pt) Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
WO2011098582A3 (en) Novel crystalline forms of ivabradine hydrochloride
BR112013029730A2 (pt) composição farmacêutica de rosuvastatina cálcica
EP3582777A4 (en) PHARMACEUTICAL COMPOSITION OF APIXABAN
BR112012032248A2 (pt) composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
BR112017025427A2 (pt) composição farmacêutica oral
BR112013002591A2 (pt) polialfaolefinas de elevada viscosidade estáveis em cisalhamento
WO2012107890A3 (en) Crystal forms of lurasidone chlorhydrate
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
EP2697238A4 (en) SOLID FORMS OF ANTIRETROVIRUS COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITION
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
BR112017001958A2 (pt) composições de núcleo
WO2012172438A3 (en) Compositions and methods for modulating a kinase
ECSP14027739A (es) Métodos para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro
ECSP13012459A (es) Valsartan altamente cristalino
AP2012006280A0 (en) Synthesis process, and crystalline form of 4-ä3-ÄCis-hexahydrocyclopentaÄCÜpyrrol-2(1H)-YLÜpropoxyübenzamide hydrochloride and pharmaceutical compositions containing it.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]